ADPKD, tolvaptan, and nephrolithiasis risk

Additional Metadata
Keywords	calcium, cyclic AMP, cystic kidney, hypercalciuria, kidney stones, kidney tubule, polycystic kidney disease, risk factors, polycystic kidney, autosomal dominant, tolvaptan, kidney calculi
Persistent URL	doi.org/10.2215/CJN.07610520, hdl.handle.net/1765/128750
Journal	Clinical Journal of the American Society of Nephrology
Rights	No Subscription.
Organisation	Department of Internal Medicine
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Zietse, B. (2020). ADPKD, tolvaptan, and nephrolithiasis risk. Clinical Journal of the American Society of Nephrology, 15(7), 923–925. doi:10.2215/CJN.07610520

Publication